- Established distribution across North America and Australia with distributors such as UFA, Neogen, and Practical Systems
- Total sales to date $700,000; 175+ registered enterprises with a combined 376 farms (unaudited)
- Registered trademarks in the U.S. and internationally with 14 U.S. and international patents granted and filed
- Winner of Asia Pacific Information and Communications Technology Alliance Awards (APICTA) and at AIIA’s iAwards
- Notable press from industry publications including Clay & Milk, Pork Business, and The Farm Weekly
- Total Amount Raised: US $237,500
- Total Round Size: US $1,300,000
- Seed :
- Minimum Investment: US $1,000 per investor
- : Crowd Note
- US $7,000,000 :
- Side by Side Offering
automed is an automatic livestock medication system. With one single system, users can automatically calculate, deliver, and record livestock treatments, and effectively manage their operations. Powerful and easy to use, the automed system integrates easily with existing livestock tools and farm management systems. The automed device automatically calculates and delivers both fixed and weight based treatments simply by synchronizing with the automed app.
automed serves the beef, pork, and sheep industries. It is focused on sustainably raising livestock with consumer confidence. It is more than just a delivery device, it is a complete solution. It is designed to automate the entire process of medicating livestock; dosing is just the beginning.
The device has been designed and built with the user in mind. With its sleek, compact design, the delivery device is easy to hold and use. The delivery device connects to adapters for injection, oral and drench, pour-on and intra-nasal, and fits comfortably in the user's hand.
- Automatic delivery
- Ergonomic design
- 1-second dose speed
- Weight-based dosing
- Real-time automatic data recording
- Secure medication and treatment records
- Built-in RFID reader
- Communications with weight scales and RFID readers
The automed adapters allow users to administer medication through injection, drench, pour-on, and intra-nasal. Once the adapter has been configured for a particular medication, the system will automatically recognize what medication is connected. Users can automatically record medication delivery without the need to further manual entry.
automed Essentials is the base package required by the users of the automed system. It contains the necessary hardware to start treating livestock with accurate doses. Users receive basic access to the automed Essentials app.
The automed Enterprise subscription package is an add-on to automed Essentials, providing more advanced features and the ability to scale automed to user's operations. It offers the full automed inventory management system experience while providing the ability to extend the system to work across multiple sites/locations.
An open integration platform allows other software systems and cloud solutions to develop extensions so customer-specific data can be incorporated into overall management systems. automed enhances partner products by expanding features and functionality, bridging gaps, and reducing development resources.
There are three revenue streams with the automed system: delivery device, adapters, and software platform.
The automed delivery device is sold as a one-off hardware cost to the end user. The adapters are sold as required by the customer. This is similar to a printer and print cartridges model. The device has a 2 to 3-year lifespan and the adapters are used to deliver between 3,000 to 10,000 doses and then replaced. In some operations, adapters will be replaced weekly or monthly depending on the amount of use.
The device retails for $1,350. The automed software solution is sold as a month-to-month subscription and is priced at $49 per enterprise and $10 per site. As an example, if a swine producer had 10 facilities this would be $49/month for the enterprise and $10/facility per month and equal a total of $149/month.
Pharmaceutical – automed has been working with pharmaceutical companies in the swine and beef industries since early 2014.
Producers – our focus globally is on:
- Swine and beef in North America
- Swine in Europe
- Sheep and beef in Australia
Where the automed system surpasses others is in its light, robust, ergonomic design, and disposable delivery adapter. These aspects are the top-rated advantages amongst automed users, including the data capture aspect. Livestock producers who are recording treatments are also impressed with automed’s ability to automatically record data as treatments are being given, providing more accurate, tamper-resistant data sets for their use, whether it be for external auditing or internal budgeting and operational analysis. automed also provides users significant savings through the system’s ability to connect to a scale, and automatically calculate the optimum dose rate for each animal based on the parameters of the medication and the animal’s weight.
automed was founded in 2012 by David and Samira Edwards with the vision to advance animal health globally by combining medical treatments and technology. First attempts resulted in a product that had a viable design but was ultimately too expensive and, in our opinion, ahead of its time. Not discouraged in the least, David decided to keep pursuing his idea until he found a viable solution that was more cost-effective to produce. This idea would become automed. The focus became two projects: a simple data capture application and the hardware device. With over 335,991(as of January 15) successful doses completed, an ever-growing national and internal customer base, and increasing awareness of the importance of making medicating livestock easier and more efficient, automed is just getting started.
The mission of automed is to instill confidence in consumers and producers by connecting the animal, user, farm, and medication through an integrated, traceable, and compliant system for livestock medication treatment.
We were originally founded in 2006. The original automed concept developed with a major focus on the sheep industry. Over the next 4 years, automed was developed as a side project by David while still working full time. At the time, David worked on a solution that would connect to an existing scale head and RFID reader. The solution was a power-driven delivery device with an in-built RFID reader. In 2012, on the 24th of August, Davoodi Pty Ltd (later changed to automed Pty Ltd) was founded by David Edwards and Samira Davoodi. The focus was on completing development of the automatic medication delivery system previously conceived by David back in 2006. In 2016, automed USA LLC was founded, followed by the first sale of the automed system in the USA. Then, in 2018, we did a Reverse merger from the AUS company to the US company, making the US company the overall group company.
To date automed has 195 registered enterprises with 376 farms. This also equates to 1930 total users.
For David Edwards, $168,000: this has been set as the minimum by the Department of Labor as per the E3 visa requirements. This salary has only been in place since November 2018.
The AM05 is released along with the application and cloud solution which includes treatment data and software data. With the application the Essentials App was recently released, which now allows smaller producers to utilize weight-based dosing without having to have the Enterprise Subscription. With the essentials app there is no data recorded or compliance. It is purely used to connect to a scale and automatically calculate the dose based off the animal’s weight. Hardware improvement are in the process to develop into the automed Set and Forget. There has been a push from customers to make the delivery device not dependent on the app. With this automed is developing the AM05+ Set and Forget. Managers will be able to set up the device and adapters initially, then all the user has to do is clip the adapter on and go vaccinate animals. At the end of the day the user will take the device back into the office and connect to WiFi which will then do a data dump to the cloud.
A Side by Side offering refers to a deal that is raising capital under two offering types. If you plan on investing less than US $20,000.00, you will automatically invest under the Regulation CF offering type. If you invest more than US $20,000.00, you must be an accredited investor and invest under the Regulation D offering type.
US $17,500 (under Reg CF only)
All non-Major Purchasers will be subject to an Investment Proxy Agreement (“IPA”). The IPA will authorize an investment Manager to act as representative for each non-Major Purchaser and take certain actions for their benefit and on their behalf. Please see a copy of the IPA included with Company's offering materials for additional details.
Investors who invest $50,000 or less will have their securities held in trust with a Custodian that will serve as a single shareholder of record. These investors will be subject to the Custodian’s Account Agreement, including the electronic delivery of all required information.
Tier 1: All Investors
- Goodie bag including an automed backpack, automed shirt, and automed tumbler
Tier 2: Investors $25,000
- All of the above
- Monthly investor update email
Tier 3: Investors $50,000
- All of the above
- Personalized supporters plaque
Tier 4: Investors $100,000+
- All of the above
- Monthly phone call with CEO
- First three investors over $100,000 will receive an invitation to the automed new facility opening on April 25, 2019, with airfare and accommodation, to meet the automed team.
It is advised that you consult a tax professional to fully understand any potential tax implications of receiving investor perks before making an investment.
The graph below illustrates theor the of automed's prior rounds by year.
Please see the financial information listed on the cover page of the Form C and attached below in addition to the following information. Financial statements are attached to the Form C as Exhibit B.
Automed PTY LTD was organized on August 24, 2012, under the laws of New South Wales, Australia, and is headquartered in Canberra, Australia. The Company was formed to develop and market for sale its livestock treatment system. The automed system allows livestock producers of all sizes to calculate, deliver, and record livestock treatments through a single automated system that easily integrates with existing livestock tools and farm management systems.
Automed, LLC was organized on June 27, 2016, under the laws of the State of Iowa, and is headquartered in Ames, Iowa. Automed, LLC was formed for the same purpose as outlined above, except to be solely focused on the North American market. On July 2, 2018, automed, LLC filed articles of conversion in the State of Iowa to convert from a limited liability company to a C‐corporation, and amended its name to automed, Inc (“the Company”).
Alongside the conversion the members of automed PTY LTD executed a contribution agreement by which the members of automed PTY LTD became stockholders of the Company, with automed PTY LTD (“the Subsidiary”) becoming a wholly‐owned subsidiary of the Company. The membership interests transferred were not altered as part of the exchange. For financial statement purposes, the transaction was treated as a reverse acquisition by the Company, with the Company being the acquirer, and the Subsidiary the acquiree. Accordingly, the Company’s financial statements have been prepared to give retroactive effect to the reverse acquisition and represent the operations of the Subsidiary.
Liquidity and Capital Resources
The proceeds from the Offering are essential to our operations. We plan to use the proceeds as set forth above under "Use of Proceeds", which is an indispensable element of our business strategy. The Offering proceeds will have a beneficial effect on our liquidity, as we have approximately $200,498 in cash on hand as of November 30, 2018 which will be augmented by the Offering proceeds and used to execute our business strategy.
The Company currently does not have any additional outside sources of capital other than the proceeds from the Combined Offerings.
Capital Expenditures and Other Obligations
The Company does not intend to make any material capital expenditures in the future.
Trends and Uncertainties
After reviewing the above discussion of the steps the Company intends to take, potential Purchasers should consider whether achievement of each step within the estimated time frame is realistic in their judgment. Potential Purchasers should also assess the consequences to the Company of any delays in taking these steps and whether the Company will need additional financing to accomplish them.
The financial statements are an important part of the Form C and should be reviewed in their entirety. The financial statements of the Company are attached to the Form C as Exhibit B.
Consumers are demanding to understand more about how their food is produced and where it comes from. An example of this is the increased demand for antibiotic-free food and traceability.
Due to this demand, supply-chain retailers such as McDonalds and Wal-Mart, are developing and looking for solutions to utilize data from livestock producers to validate the products supplied and how they were produced.
With the increasing need from supply-chain to require these records, livestock producers are looking for solutions to capture this data and increase production efficiency.
This has led to pressure on the pharmaceutical industry to improve livestock medication stewardship and work with the livestock industry to improve regulatory requirements.
This opportunity is allowing automed to provide an industry solution for consumers, supply-chain, producers, and pharmaceutical companies.
automed has market opportunities in North America, Europe, and Australia, considering manual delivery devices and disposable syringes (that lack the ability for data capture) which we estimate account for 98% of what is used currently in the market. The total market potential for the automed system is $4.92 billion. This equates to 5.2 million devices and 1 million annual software licenses. In analyzing the total serviceable market potential, it is estimated to be $50 million over the next 5 years.
The reviewing CPA has included a “going concern” note in the reviewed financials. Specifically, the notes state: “The Company has incurred losses from inception of approximately $1,793,363 and relies on third‐parties to finance operations which, among other factors, raises substantial doubt about the Company's ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon management's plans to raise additional capital from the issuance of debt or the sale of stock, its ability to commence profitable sales of its flagship product, and its ability to generate positive operational cash flow. The accompanying financial statements do not include any adjustments that might be required should the Company be unable to continue as a going concern.” Its costs may also increase due to such factors as higher than anticipated financing and other costs; non-performance by third-party suppliers, licensees, partners or subcontractors; and increases in the costs of labor or materials. If any of these or similar factors occur, its net losses and accumulated deficit could increase significantly and the value of its stock could decline.
We have not prepared any audited financial statements. Therefore, you have no audited financial information regarding the Company’s capitalization or assets or liabilities on which to make your investment decision. If you feel the information provided is insufficient, you should not invest in the Company.
The Company forecasts project aggressive growth in revenue from 2018 to 2019. If its assumptions are wrong, and its projections regarding market penetration are too aggressive, its financial projections may overstate its viability. In addition, the forward-looking statements are only predictions. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
The Company’s business model is capital intensive. The amount of capital the Company is attempting to raise in this Offering is not enough to sustain the Company’s current business plan. In order to achieve the Company’s near and long-term goals, the Company will need to procure funds in addition to the amount raised in the Offering. There is no guarantee the Company will be able to raise such funds on acceptable terms or at all. If the Company are not able to raise sufficient capital in the future, it will not be able to execute its business plan, its continued operations will be in jeopardy and it may be forced to cease operations and sell or otherwise transfer all or substantially all of its remaining assets, which could cause a Purchaser to lose all or a portion of his or her investment.
The Company’s expenses will significantly increase as they seek to execute their current business model. Although the Company estimates that it has enough runway until end of year, they will be ramping up cash burn to promote revenue growth, increase payroll, further develop R&D, and fund other Company operations after the raise. Doing so could require significant effort and expense or may not be feasible.
The Company’s success depends on the experience and skill of the board of directors, its executive officers and key employees. In particular, the Company is dependent on David Edwards. There can be no assurance that they will continue to be employed by the Company for a particular period of time. The loss of our key employees or any member of the board of directors or executive officer could harm the Company’s business, financial condition, cash flow and results of operations.
The Company’s Co-founders, David Edwards and Samira Edwards, are married. This could introduce unique risks, given the idiosyncrasies of interpersonal relationships. Interpersonal issues such as divorce or severe disruption in a familial relationship could disrupt the day-to-day operation of the business, and could negatively impact the financial position of the Company.
Industry consolidation may result in increased competition, which could result in a loss of customers or a reduction in revenue. Some of our competitors have made or may make acquisitions or may enter into partnerships or other strategic relationships to offer more comprehensive services than they individually had offered or achieve greater economies of scale. In addition, new entrants not currently considered to be competitors may enter our market through acquisitions, partnerships or strategic relationships. We expect these trends to continue as companies attempt to strengthen or maintain their market positions. The potential entrants may have competitive advantages over us, such as greater name recognition, longer operating histories, more varied services and larger marketing budgets, as well as greater financial, technical and other resources. The companies resulting from combinations or that expand or vertically integrate their business to include the market that we address may create more compelling service offerings and may offer greater pricing flexibility than we can or may engage in business practices that make it more difficult for us to compete effectively, including on the basis of price, sales and marketing programs, technology or service functionality. These pressures could result in a substantial loss of our customers or a reduction in our revenue.
The Company’s cash position is relatively weak. The Company currently had $200,000 in cash balances as of November 20, 2018 . The Company believes that it is able to continue extracting cash from sales to extend its runway. The Company could be harmed if it is unable to meet its cash demands, and the Company may not be able to continue operations if they are not able to raise additional funds.
The Company’s sales cycle is long and may be unpredictable, which can result in variability of its financial performance. Additionally, long sales cycles may require the Company to incur high sales and marketing expenses with no assurance that a sale will result, which could adversely affect its profitability. The Company’s results of operations may fluctuate, in part, because of the resource-intensive nature of its sales efforts and the length and variability of the sales cycle. A sales cycle is the period between initial contact with a prospective customer and any sale of its products and services. The sales process involves educating customers about the Company’s products and services, participating in extended evaluations and configuring the products and services to customer-specific needs. The length of the sales cycle, from initial contact with a customer to the execution of a purchase order, may take a number of months. During the sales cycle, the Company may expend significant time and money on sales and marketing activities or make other expenditures, all of which lower its operating margins, particularly if no sale occurs or if the sale is delayed as a result of extended qualification processes or delays. It is difficult to predict when, or even if, it will make a sale to a potential customer or if the Company can increase sales to existing customers. As a result, the Company may not recognize revenue from sales efforts for extended periods of time, or at all. The loss or delay of one or more large transactions in a quarter could impact its results of operations for that quarter and any future quarters for which revenue from that transaction is lost or delayed.
The Company has outstanding liabilities. In particular, as of the financial year ending June 30, 2018, the Company owed $437,079 in total current liabilities, including liabilities for accounts payable ($91,397), accrued expenses ($225,836), customer pre-payments ($105,795), shareholder advances ($9,669), and notes payable ($4,382). In addition to current debt, the Company also has other liabilities including, as of the financial year ending June 30, 2018, Related Party notes payable ($919,211), and other notes payable equalling $26,490 and $50,000 respectively. In total, the Company’s liability was $1,432,780 as of the financial year end.
The Company has not filed a Form D for its prior offerings. The SEC rules require a Form D to be filed by companies within 15 days after the first sale of securities in the offering relying on Regulation D. Failing to register with the SEC or get an exemption may lead to fines, the right of investors to get their investments back, and even criminal charges. There is a risk that a late penalty could apply.
Start-up investing is risky. Investing in startups is very risky, highly speculative, and should not be made by anyone who cannot afford to lose their entire investment. Unlike an investment in a mature business where there is a track record of revenue and income, the success of a startup or early-stage venture often relies on the development of a new product or service that may or may not find a market. Before investing, you should carefully consider the specific risks and disclosures related to both this offering type and the company which can be found in this company profile and the documents in the data room below.
Your shares are not easily transferable. You should not plan on being able to readily transfer and/or resell your security. Currently there is no market or liquidity for these shares and the company does not have any plans to list these shares on an exchange or other secondary market. At some point the company may choose to do so, but until then you should plan to hold your investment for a significant period of time before a “liquidation event” occurs. A “liquidation event” is when the company either lists their shares on an exchange, is acquired, or goes bankrupt.
The Company may not pay dividends for the foreseeable future. Unless otherwise specified in the offering documents and subject to state law, you are not entitled to receive any dividends on your interest in the Company. Accordingly, any potential investor who anticipates the need for current dividends or income from an investment should not purchase any of the securities offered on the Site.
Valuation and capitalization. Unlike listed companies that are valued publicly through market-driven stock prices, the valuation of private companies, especially startups, is difficult to assess and you may risk overpaying for your investment. In addition, there may be additional classes of equity with rights that are superior to the class of equity being sold.
You may only receive limited disclosure. While the company must disclose certain information, since the company is at an early-stage they may only be able to provide limited information about its business plan and operations because it does not have fully developed operations or a long history. The company may also only obligated to file information periodically regarding its business, including financial statements. A publicly listed company, in contrast, is required to file annual and quarterly reports and promptly disclose certain events through continuing disclosure that you can use to evaluate the status of your investment.
Investment in personnel. An early-stage investment is also an investment in the entrepreneur or management of the company. Being able to execute on the business plan is often an important factor in whether the business is viable and successful. You should be aware that a portion of your investment may fund the compensation of the company's employees, including its management. You should carefully review any disclosure regarding the company's use of proceeds.
Possibility of fraud. In light of the relative ease with which early-stage companies can raise funds, it may be the case that certain opportunities turn out to be money-losing fraudulent schemes. As with other investments, there is no guarantee that investments will be immune from fraud.
Lack of professional guidance. Many successful companies partially attribute their early success to the guidance of professional early-stage investors (e.g., angel investors and venture capital firms). These investors often negotiate for seats on the company's board of directors and play an important role through their resources, contacts and experience in assisting early-stage companies in executing on their business plans. An early-stage company may not have the benefit of such professional investors.
Representatives of SI Securities, LLC are affiliated with SI Advisors, LLC (“SI Advisors”). SI Advisors is an exempt investment advisor that acts as the General Partner of SI Selections Fund I, L.P. (“SI Selections Fund”). SI Selections Fund is an early stage venture capital fund owned by third-party investors. From time to time, SI Selections Fund may invest in offerings made available on the SeedInvest platform, including this offering. Investments made by SI Selections Fund may be counted towards the total funds raised necessary to reach the minimum funding target as disclosed in the applicable offering materials.
Frequently Asked Questions
A Side by Side offering refers to a deal that is raising capital under two offering types. This Side by Side offering is raising under Regulation CF and Rule 506(c) of Regulation D.
The Form C is a document the company must file with the Securities and Exchange Commission (“SEC”) which includes basic information about the company and its offering and is a condition to making a Reg CF offering available to investors. It is important to note that the SEC does not review the Form C, and therefore is not recommending and/or approving any of the securities being offered.
Before making any investment decision, it is highly recommended that prospective investors review the Form C filed with the SEC (included in the company's profile) before making any investment decision.
Rule 506(c) under Regulation D is a type of offering with no limits on how much a company may raise. The company may generally solicit their offering, but the company must verify each investor’s status as an accredited investor prior to closing and accepting funds. To learn more about Rule 506(c) under Regulation D and other offering types check out our blog and academy.
Title III of the JOBS Act outlines Reg CF, a type of offering allowing private companies to raise up to $1 million from all Americans. Prior capital raising options limited private companies to raising money only from accredited investors, historically the wealthiest ~2% of Americans. Like a Kickstarter campaign, Reg CF allows companies to raise funds online from their early adopters and the crowd. However, instead of providing investors a reward such as a t-shirt or a card, investors receive securities, typically equity, in the startups they back. To learn more about Reg CF and other offering types check out our blog and academy.
When you complete your investment on SeedInvest, your money will be transferred to an escrow account where an independent escrow agent will watch over your investment until it is accepted by automed. Once automed accepts your investment, and certain regulatory procedures are completed, your money will be transferred from the escrow account to automed in exchange for your securities. At that point, you will be a proud owner in automed.
To make an investment, you will need the following information readily available:
- Personal information such as your current address and phone number
- Employment and employer information
- Net worth and income information
- Social Security Number or passport
- ABA bank routing number and checking account number (typically found on a personal check or bank statement)
If you are investing under Rule 506(c) of Regulation D, your status as an Accredited Investor will also need to be verified and you will be asked to provide documentation supporting your income, net worth, revenue, or net assets or a letter from a qualified advisor such as a Registered Investment Advisor, Registered Broker Dealer, Lawyer, or CPA.
An investor is limited in the amount that he or she may invest in a Reg CF offering during any 12-month period:
- If either the annual income or the net worth of the investor is less than $100,000, the investor is limited to the greater of $2,000 or 5% of the lesser of his or her annual income or net worth.
- If the annual income and net worth of the investor are both greater than $100,000, the investor is limited to 10% of the lesser of his or her annual income or net worth, to a maximum of $100,000.
Separately, automed has set a minimum investment amount of US $1,000.
Accredited investors investing $20,000 or over do not have investment limits.
You are a partial owner of the company, you do own securities after all! But more importantly, companies which have raised money via Regulation CF must file information with the SEC and post it on their websites on an annual basis. Receiving regular company updates is important to keep shareholders educated and informed about the progress of the company and their investment. This annual report includes information similar to a company’s initial Reg CF filing and key information that a company will want to share with its investors to foster a dynamic and healthy relationship.
In certain circumstances a company may terminate its ongoing reporting requirement if:
- The company becomes a fully-reporting registrant with the SEC
- The company has filed at least one annual report, but has no more than 300 shareholders of record
- The company has filed at least three annual reports, and has no more than $10 million in assets
- The company or another party purchases or repurchases all the securities sold in reliance on Section 4(a)(6)
- The company ceases to do business
However, regardless of whether a company has terminated its ongoing reporting requirement per SEC rules, SeedInvest works with all companies on its platform to ensure that investors are provided quarterly updates. These quarterly reports will include information such as: (i) quarterly net sales, (ii) quarterly change in cash and cash on hand, (iii) material updates on the business, (iv) fundraising updates (any plans for next round, current round status, etc.), and (v) any notable press and news.
Currently there is no market or liquidity for these securities. Right now automed does not plan to list these securities on a national exchange or another secondary market. At some point automed may choose to do so, but until then you should plan to hold your investment for a significant period of time before a “liquidation event” occurs. A “liquidation event” is when automed either lists their securities on an exchange, is acquired, or goes bankrupt.
You can return to SeedInvest at any time to view your portfolio of investments and obtain a summary statement. If invested under Regulation CF you may also receive periodic updates from the company about their business, in addition to monthly account statements.
This is automed's fundraising profile page, where you can find information that may be helpful for you to make an investment decision in their company. The information on this page includes the company overview, team bios, and the risks and disclosures related to this investment opportunity. If the company runs a side by side offering that includes an offering under Regulation CF, you may also find a copy of the automed's Form C. The Form C includes important details about automed's fundraise that you should review before investing.
For offerings made under Regulation CF, you may cancel your investment at any time up to 48 hours before a closing occurs or an earlier date set by the company. You will be sent a reminder notification approximately five days before the closing or set date giving you an opportunity to cancel your investment if you had not already done so. Once a closing occurs, and if you have not canceled your investment, you will receive an email notifying you that your securities have been issued. If you have already funded your investment, your funds will be promptly refunded to you upon cancellation. To cancel your investment, you may go to your portfolio page
If you invest under any other offering type, you may cancel your investment at any time, for any reason until a closing occurs. You will receive an email when the closing occurs and your securities have been issued. If you have already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To cancel your investment, please go to your portfolio page.